Sorafenib

Schlüsselwörter

Sorafenib - Tyrosin-Kinase-Inhibitor

Keywords

sorafenib - tyrosine kinase inhibitor

Literatur

• 1 Cheng A L, Kang Y K, Chen Z, Tsao C J, Qin S, Kim J S. et al . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.  Lancet Oncol. 2009;  10 25-34
• 2 Escudier B, Eisen T, Stadler W M, Szczylik C, Oudard S, Siebels M. et al, TARGET Study Group . Sorafenib in advanced clear-cell renal-cell carcinoma.  N Engl J Med. 2007;  356 125-134
• 3 Escudier B, Eisen T, Stadler W M, Szczylik C, Oudard S, Staehler M. et al . Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.  J Clin Oncol. 2009;  27 3312-3318
• 4 Escudier B, Szczylik C, Hutson T E, Demkow T, Staehler M, Rolland F. et al . Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.  J Clin Oncol. 2009;  27 1280-1289
• 5 Fachinformation Sorafenib. Stand Juni 2009
• 6 Force T, Krause D S, Van Etten R A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.  Nat Rev Cancer. 2007;  7 332-344
• 7 Hauschild A, Agarwala S S, Trefzer U, Hogg D, Robert C, Hersey P. et al . Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.  J Clin Oncol. 2009;  27 2823-2830
• 8 Llovet J M, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J F, SHARP I nvestigators Study Group. et al . Sorafenib in advanced hepatocellular carcinoma.  N Engl J Med. 2008;  359 378-390
• 9 May D, Gilon D, Djonov V, Itin A, Lazarus A, Gordon O. et al . Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation.  Proc Natl Acad Sci U S A. 2008;  105 282-287
• 10 McDermott D F, Sosman J A, Gonzalez R, Hodi F S, Linette G P, Richards J. et al . Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11 715 Study Group.  J Clin Oncol. 2008;  26 2178-2185
• 11 Therasse P, Arbuck S G, Eisenhauer E A, Wanders J, Kaplan R S, Rubinstein L. et al . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.  J Natl Cancer Inst. 2000;  92 205-216
• 12 Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith R A. et al . Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.  Nat Rev Drug Discov. 2006;  5 835-844
• 13 Wilhelm S M, Carter C, Tang L, Wilkie D, McNabola A, Rong H. et al . BAY 43 – 9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.  Cancer Res. 2004;  64 7099-7109